Bellicum Pharmaceuticals Inc News Releases http://ir.bellicum.com/ Bellicum Pharmaceuticals Inc News Releases en Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting http://ir.bellicum.com/news-releases/news-release-details/bellicum-pharmaceuticals-provides-interim-data-bpx-601-patients Data provides further evidence that GoCAR-T ® technology boosts expansion and persistence of therapeutic T cells in patients T cell expansion and persistence greater in patients who received lymphodepletion with cyclophosphamide plus fludarabine (Flu/Cy) compared to Cy alone Of 13 patients Sat, 01 Jun 2019 09:00:00 -0400 Bellicum Pharmaceuticals Inc News Releases 9216 Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://ir.bellicum.com/news-releases/news-release-details/bellicum-pharmaceuticals-reports-inducement-grants-under-nasdaq HOUSTON , May 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced equity inducement grants to four new employees consisting of an aggregate of Fri, 31 May 2019 16:14:00 -0400 Bellicum Pharmaceuticals Inc News Releases 9211 Bellicum Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference http://ir.bellicum.com/news-releases/news-release-details/bellicum-pharmaceuticals-present-jefferies-2019-healthcare HOUSTON , May 29, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) , a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair , President and CEO, is scheduled to present a corporate Wed, 29 May 2019 16:05:00 -0400 Bellicum Pharmaceuticals Inc News Releases 9196 Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting http://ir.bellicum.com/news-releases/news-release-details/bellicum-pharmaceuticals-present-updated-results-bpx-601-2019 Preliminary results from patients treated with BPX-601 who underwent lymphodepletion with cyclophosphamide plus fludarabine to be presented HOUSTON , May 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. ( NASDAQ:BLCM ), a leader in developing novel, controllable cellular immunotherapies Wed, 15 May 2019 16:05:00 -0400 Bellicum Pharmaceuticals Inc News Releases 9181 Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update http://ir.bellicum.com/news-releases/news-release-details/bellicum-pharmaceuticals-reports-first-quarter-2019-financial Interim data for BPX-601 accepted for presentation at upcoming American Society of  Clinical Oncology ( ASCO ) Annual Meeting Rivo-cel™  on-track for topline data readout from BP-004 pediatric trial in second quarter of 2019 HOUSTON , May 07, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. Tue, 07 May 2019 07:30:00 -0400 Bellicum Pharmaceuticals Inc News Releases 9151 Bellicum Pharmaceuticals to Participate in Jefferies 6th Annual IO Cell Therapy Summit http://ir.bellicum.com/news-releases/news-release-details/bellicum-pharmaceuticals-participate-jefferies-6th-annual-io HOUSTON , March 27, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) , a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced participation in the Jefferies 6 th Annual IO Cell Therapy Summit taking Wed, 27 Mar 2019 07:30:00 -0400 Bellicum Pharmaceuticals Inc News Releases 9106 Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2018 http://ir.bellicum.com/news-releases/news-release-details/bellicum-pharmaceuticals-provides-operational-update-and-4 HOUSTON , March 12, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the fourth quarter and full year ended December 31, Tue, 12 Mar 2019 16:01:00 -0400 Bellicum Pharmaceuticals Inc News Releases 9081 Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call and Webcast on Tuesday, March 12, 2019 http://ir.bellicum.com/news-releases/news-release-details/bellicum-pharmaceuticals-report-fourth-quarter-and-full-year-0 HOUSTON , March 05, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on Tuesday, Tue, 05 Mar 2019 07:00:00 -0500 Bellicum Pharmaceuticals Inc News Releases 9071 Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors http://ir.bellicum.com/news-releases/news-release-details/bellicum-pharmaceuticals-announces-appointment-judith-klimovsky HOUSTON , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Judith Klimovsky , M.D., to its board of directors Thu, 20 Dec 2018 07:00:00 -0500 Bellicum Pharmaceuticals Inc News Releases 8946 Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO http://ir.bellicum.com/news-releases/news-release-details/bellicum-reports-safety-results-and-promising-activity-its Rimiducid-activated GoCAR-T ®  resulted in significant expansion and persistence of T cells Initial evidence of biologic activity and stable disease observed in some patients with single rimiducid dose BPX-601 was well-tolerated with no CRS or neurotoxicity reported in initial cell-dose escalation Fri, 14 Dec 2018 07:00:00 -0500 Bellicum Pharmaceuticals Inc News Releases 8931